MYCOF (MYCOF) Stock Price & Analysis
MYCOF (MYCOF) rose 0.00% to USD 2 as of June 10, 2026 at 08:47 UTC, according to Nexqual real-time market data.
MYCOF last closed at USD 2; the session ranged USD 2–2 on volume of 400 shares. Market capitalization is $117.10M, with a 52-week range of USD 0.03–2.04 (PNK). Source: Nexqual, June 10, 2026 at 08:47 UTC.
Key Statistics (as of June 10, 2026 at 08:47 UTC)
| Price | USD 2 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2 |
| Open | USD 2 |
| Day Range | USD 2 – 2 |
| 52-Week Range | USD 0.03 – 2.04 |
| Volume | 400 shares |
| Market Cap | $117.10M |
| Exchange | PNK |
Technical Analysis (MYCOF)
Nexqual's technical model rates MYCOF "BUY" based on 5 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 08:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 91.21 (overbought) |
| vs SMA50 | Above (USD 1.19) |
| MACD | 0.17 (positive) |
Analyst Ratings (MYCOF)
Wall Street analysts rate MYCOF "None", per Nexqual as of June 10, 2026 at 08:47 UTC.
| Consensus Rating | None |
|---|
Earnings (MYCOF)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-03-31 | USD -50.38 vs est -50 ▼ miss |
| 2021-12-31 | USD -51.75 vs est -50 ▼ miss |
| 2021-09-30 | USD -43.5 vs est -25 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:47 UTC.
Financials & Fundamentals (MYCOF)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.47 |
| Total Cash | $2.03M |
| Total Debt | $424,269 |
| Free Cash Flow | $-4.67M |
Source: Nexqual, June 10, 2026 at 08:47 UTC.
Financial Health Score (MYCOF)
Nexqual rates MYCOF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:47 UTC.
| Growth | Critical — Revenue -87% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Mixed — No data |
Ownership (MYCOF)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 58.55M |
| Float | 58.52M |
Source: Nexqual, June 10, 2026 at 08:47 UTC.
Leadership (MYCOF)
MYCOF is led by Jason Birmingham, CEO, President & Director, per Nexqual as of June 10, 2026 at 08:47 UTC.
| CEO, President & Director | Jason Birmingham |
|---|---|
| CFO & Corporate Secretary | John Charles Ross CA (age 67) |
| Interim CEO & Technical Director of Mindleap Health Inc. | William Cook |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVVTF | Revive Therapeutics Ltd. | USD 0.03 | ▲ 15.45% |
| HAVLF | HAVN LIFE SCIENCES INC. | USD 0 | ▲ 0% |
| TRUFF | Red Light Holland Corp. | USD 0.03 | ▲ 0.71% |
| EHVVF | Ehave Inc. | USD 0 | ▲ 0% |
| HELP | Cybin Inc. | USD 3.92 | ▼ 5.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:47 UTC. This page is informational and not investment advice.